Enterovirus 71 (EV71), a member of the enterovirus genus within the Picornaviridae family, has attracted immense global public healthcare attention. Since its initial identification in California in 1969, epidemics of EV71 infection have been reported periodically all over the world [1] [2] [3] [4] [5] . Infection with this non-enveloped RNA virus (approximately 7.5 kb in size) could induce a series of syndromes including herpangina, viraemia and hand-foot-and-mouth disease (HFMD) [6, 7] . Although the diseases caused by EV71 are mild and are self-limited in most cases, it might sometimes involve central nervous system (CNS) infection, leading to neurological sequelae and even death [8] . Children under 5 years of age are highly susceptible to EV71 and can easily develop CNS symptoms upon EV71 infection [9, 10] . A large outbreak of EV71 occurred in Taiwan in the early 1990s, with 405 severe cases and 78 mortalities reported [11] . In China, EV71 infection has also become a very important issue. In the spring of 2008, an EV71 epidemic, which occurred first in Fuyang of the Anhui Province and then rapidly spread to nearly all the other provinces in Southern China, infected >175,000 individuals and caused 44 deaths in children [12, 13] . On 4 May 2010, the Chinese Ministry of Health announced that a large EV71 outbreak in China had infected 427,728 children and caused 260 deaths between January and April 2010.
Several investigations on preventing EV71 infection have been made. Vaccines such as live-attenuated, inactivated whole virus vaccine, DNA vaccine and recombinant protein vaccine are being investigated. Unfortunately, no effective vaccines have yet to be used in clinic trials [14, 15] . Some computer-designed drugs [16, 17] , together with parts of traditional herbs [18] , were recently reported to protect cells from EV71 infection to a certain degree; however, they are all at the 1, 3 , Ming-Liang He 1, 3 Introduction experimental stages and more time is needed to further developing these agents into clinical drugs.
Interferons (IFNs), a series of structurally related glycoproteins known as cytokines [19, 20] , are notable for their intrinsic ability to interfere with viral replication. Several distinct IFNs have been identified for humans [21] and each binds to a specific receptor [22] . IFNs are classified into three major groups on the basis of their interacting receptors: type I, II and III [23] . The type I IFNs are the most common IFNs, which are massively produced in nearly all types of cells during viral infection. Through binding to the shared receptors, the type I IFNs activate numerous antiviral effectors to form a formidable network against viral reproduction [24] . It has been demonstrated that IFNs can control viral infection in every step, including viral replication, translation and the production of infectious virions by stimulating downstream target genes [25] . Each subtype of the >20 identified IFNs display different specificity and antiviral activity to a given virus. Clinically, the type I IFNs have been used to treat a number of viral infections. Studies in patients infected with various HCV genotypes have shown that patients benefit more from IFN-α2b (approximately 3-9 million units IFN thrice weekly) treatment than those from IFN-β treatment [26, 27] . In this study, we investigated the anti-EV71 activities of nearly all human type I IFNs (14 IFN-α subtypes, 1 IFN-β, 1 IFN-ω and 1 IFN-α hybrid).
Methods

Viruses and cells
Vero cells (American Type Culture Collection, Manassas, VA, USA) were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS) with 100 U/ml penicillin and 100 µg/ ml streptomycin. EV71 (SHZH98 strain; GenBank accession number AF302996) was obtained from the Shenzhen Center for Disease Control and Prevention (Shenzhen, China). To prepare virus stocks, viruses were propagated on 90% confluent monolayer cells in DMEM with 2% FBS. Viral titres were determined by cytopathic effect (CPE) microtitration assays and expressed as the 50% tissue culture infective dose (TCID 50 ) per ml according to the Kärber formula [28] .
Cytotoxicity assays
Cells (2×10 4 cells/well) were seeded into 96-well plates and incubated overnight. The medium was then removed and type I IFNs (PBL Biomedical Laboratories Inc., Piscataway, NJ, USA) were added to a final concentration of 1,000 or 10,000 U/ml. After incubation for 3 days, the cytotoxicity of IFNs was observed under a microscope.
Cytopathic effect assays
The antiviral activities of type I IFNs were determined by CPE assays. Vero cells (2×10 4 cells/well) were seeded into 96-well plates. After incubation for 24 h, the culture medium was replaced with fresh DMEM containing one of the 17 IFN subtypes at final concentrations of 0, 10, 100 and 1,000 U/ml. After pretreatment with IFNs for 6 h, the medium was then removed and the cells were washed with phosphate-buffered saline (PBS). Subsequently, the cells were mock-infected or infected with 100 TCID 50 EV71 for 1 h. The medium was removed and the cells were washed again with PBS and cultured in DMEM with 2% FBS for 3 days. The CPE was monitored and recorded daily by using a phase-contrast microscope.
Cytoprotection assays
The cytoprotective activity was determined by 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide (MTT) assays, as described elsewhere [17, 29] . Briefly, Vero cells (2×10 4 cells/well) were seeded into 96-well culture plates and were incubated overnight. The medium was then removed and the cells were treated without or with indicated type I IFNs for 6 h. Subsequently, the cells were mock-infected or infected with 100 TCID 50 EV71 for 1 h. The cells were washed again and cultured in DMEM with 2% FBS. After a 72 h incubation, MTT was added to reach a final concentration of 0.5 mg/ml followed by a 4 h incubation. After removal of culture medium, 100 µl of dimethyl sulfoxide was added. The absorbance (A) was measured in a 96-well plate reader at 492 nm with a reference of 620 nm. The cytoprotection rate was calculated using the following formula: (A492t-A492v)/(A492c-A492v)×100%, where A492t is the absorbance of the infected cells treated with IFNs, A492v is the absorbance of the infected cells with mock treatment and A492c is the absorbance of the untreated mock-infected cells. The 50% inhibitory concentration (IC 50 ) value was calculated by the improved Kärber method.
Quantitative real-time PCR
The total RNA was isolated from mock-treated or IFN-treated cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Then, 1 µg of total RNA was reverse transcribed into complementary DNA using the Reverse Transcription System (Promega, Madison, WI, USA). The quantitative real-time PCR was carried out using an ABI 7500 Real-Time PCR System with Power SYBR Green Master Mix (Applied Biosystems, Carlsbad, CA, USA). The PCR reaction was set up under the following thermal cycling conditions: 95°C for 10 min, 45 cycles of 95°C for 15 s and 60°C for 1 min. Fluorescence signals were collected by the machine during the extension phase of each PCR cycle. The primers used in this study are listed in Table 1 . The cycle threshold value was normalized to that of GAPDH.
Statistical analyses
Results are expressed as mean ±sd. All statistical analyses were carried out with SPSS version 14.0 software (SPSS Inc., Chicago, IL, USA). Two-tailed Student's t-test was applied for two-group comparison. A P-value <0.05 was considered statistically significant.
Results
Screening for potent IFNs against EV71
To identify highly efficient IFNs against EV71, we screened nearly all human type I IFNs (14 IFN-α subtypes, 1 IFN-β, 1 IFN-ω and 1 IFN-α hybrid). The antiviral activities of these IFNs were blindly scored by two scientists independently. The CPE induced by EV71 was monitored under phase-contrast microscopy at different time points. As shown in Figure  1 , the non-infected cells normally grow flat and are attached firmly on the culture plate. After infection with EV71, the cells changed shape. Initially, the cells became round and more refractile. As the infection progressed, some infected cells detached from the culture plate and floated in the medium. EV71 resulted in an obvious CPE at 48 h after the cells were infected with EV71 without IFN treatment (Figure 1 ). The CPE was reduced at varying degrees when the cells were pretreated with IFNs. The CPE was slightly repressed when the cells were treated with 100 U/ml of IFN-α2a (Figure 1 ), but was reduced significantly when the cells were treated with several IFNs, such as IFN-α14, at the same concentration. In the case of IFN-α2b treatment, no obvious cytoprotection was observed (Figure 1) . If the concentration was increased to 1,000 U/ ml, the CPE was further reduced for cells preincubated with IFN-α2a and IFN-α14; IFN-α2b displayed mild anti-EV71 activity. As summarized in Table 2 , IFN-α4, IFN-α6, IFN-α14 and IFN-α16 exhibited the most potent anti-EV71 activity, which protected up to 50% of Vero cells even at a low concentration (100 U/ml). Their anti-EV71 activities were much higher than those of IFN-α2a and the universal type I IFN (an IFN-α hybrid constructed from recombinated IFN-α2a and IFN-α1). Both IFN-α2a and the universal type I interferon markedly inhibited CPE at a high concentration, but showed little cell protective activity at a low concentration. The other tested IFNs only had minimal cytoprotective activity as no obvious CPE reduction was observed. The cells in these groups died almost the same as the mock-treated cells. No cytotoxicity was discovered when cells were cultured with high dose of IFNs (10 4 U/ml) after a 3-day incubation period (Yi, et al., data not shown).
Validation of effective IFNs
To validate the results above, we randomly chose four IFNs (two of the most effective IFNs, a less effective IFN [the universal type I IFN] and the conventional IFN-α2a) to test their cytoprotective activities in detail
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GenBank accession number Direction Sequences of primers by using MTT assays. Results were highly consistent with our previous observations. Again, IFN-α14 and IFN-α16 showed the highest activity in cytoprotection. The viability of Vero cells infected with EV71 was significantly increased even at low concentrations ( Figure 2 ). The IC 50 was 188 and 531 U/ml for IFN-α14 and IFN-α16, respectively. IFN-α2a and the universal type I IFN could only increase the viability of the infected cells by approximately 40% at a concentration of 1,000 U/ml. The IC 50 was 3,783 and 4,243 U/ml, respectively.
Inhibition of viral replication by IFN treatment prior to infection
To compare the antiviral effect of different IFNs, we tested their ability to inhibit viral replication. We determined the levels of viral RNA at 48 h post-infection. As shown in Figure 3 , both IFN-α2a and IFN-α14 inhibited EV71 replication in a dose-dependent manner. The IC 50 of IFN-α2a was 220 U/ml. In the case of IFN-α14, the IC 50 was 10 U/ml. The virus yield was reduced by 50.2% and 91.6% when the cells were pretreated with 10 U/ml and 10 4 U/ml of IFN-α14, respectively. However, when the cells were pretreated with IFN-α2a at the same concentrations, the virus yield was only reduced by 26.7% and 79.3%, respectively.
Inhibitory kinetics of IFN-α2a and IFN-α14
We further determined the viral kinetics of EV71 in Vero cells pretreated with or without IFN-α2a and IFN-α14. As shown in Figure 4 , in the case of the mock-treated cells, the intracellular viral RNA levels continuously increased to 10,000-fold between 5 and 72 h. After treatment with IFNs, EV71 replication was significantly inhibited. The viral load was markedly reduced by IFNα2a treatment after 20 h post-infection. Consistently, the RNA levels of EV71 decreased more obviously when the cells were pretreated with IFN-α14. The EV71 RNA levels were 36.8% and 15.1% of virus control group at 48 h post-infection when cells were treated with IFN-α2a and IFN-α14, and 9.6% and 1.2% at 72 h post-treatment, respectively. In the case of extracellular viruses, similar results were also observed (Yi, et al., data not shown).
Inhibition of viral replication by IFN treatment upon or after infection
After validating the antiviral effects of IFN-α2a and IFN-α14 treatment prior to viral infection, it was of interest to know the effects of treatment upon or after EV71 infection. As shown in Figure 5 , in both cases, IFNs obviously inhibited the EV71 replication. Again, IFN-α14 exhibited much stronger anti-EV71 activity than IFN-α2a. There was no significant statistical difference among the tested time points of treatment.
Antiviral effectors induced by IFN-α2a and IFN-α14
To investigate the antiviral mechanism mediated by IFN-α14, we measured the messenger RNA (mRNA) levels of IFN-induced antiviral effectors, including 2′-5′-oligoadenylate synthetase (OAS)1, OAS2, OASL, ribonuclease L (RNase L), eukaryotic translation initiation factor-2 α-kinase 2 (PKR), myxovirus (influenza virus) resistence-1 (Mx1) and IFN-stimulated gene (ISG15 and OASL were increased 1,887-and 5,662-fold by IFN-α14, whereas they were only increased 15-and 90-fold by IFN-α2a, respectively ( Figure 6 ).
Discussion
To date, there are approximately 20 different human type I IFNs identified. Although they are highly homologous in amino acid sequences and share the same receptors, the biological effect of each IFN is apparently different. In this study, we tested the anti-EV71 activities of 17 human type 1 IFNs. Consistent with previous studies [30] , IFN-α2a showed relatively weak antiviral activity, indicating that it is not suitable for the treatment of EV71 infection. Out of 17 IFNs, we showed that four IFNs (IFN-α4, IFN-α6, IFN-α14 and IFN-α16) potently reduced CPE induced by EV71, which might be useful for anti-EV71 treatment in the future.
Over the past two decades, type I IFNs have been successfully used to combat virus as well as a range of other diseases [31, 32] . However, when it comes to expend its clinical application, lots of questions still need to be solved. One of the most frequent problems is their significant toxicities at high doses. It is reported that approximately 30% of patients required dose reduction in pivotal clinical trials because of adverse effects such as neutropaenia and thrombocytopaenia. Although it is safe to treat patients infected with HBV or HCV with 1 million units of IFN-α2a per shot in current clinical settings, some patients have strong side effects, such as fever or vomiting. Unquestionably, highly active IFNs are desperately in need as they can reduce the administrative dose and therefore greatly lessen the toxicity. IFNs with low IC 50 values will be no doubt in favour of its clinical application. In this study, we showed that 4 of 17 IFNs had great potential for treating EV71 infection. They all showed similar antiviral activities in screening assays. To characterize the antiviral effects in detail, IFN-α14 was further investigated. Compared with conventional IFN- α2a, IFN-α14 displayed much higher anti-EV71 activity. The concentration required to inhibit the 50% CPE caused by EV71 was 188 U/ml, which was 20× less than that of IFN-α2a. Consistently, the IC 50 value was also 20× less than that of IFN-α2a. Considering that 10 4 U/mouse of recombinant mouse IFN-α2a could increasingly improve the survival rate of newborn mice after EV71 challenge [30] , we have reason to expect more efficient therapeutic response and less adverse effect from four potent IFNs in our research. Furthermore, we have shown that IFN-α14 could inhibit viral replication whether added before or after viral infection. This potent effectiveness of IFN-α14 against EV71 could be beneficial for treatment.
To further reveal the superior anti-EV71 mechanism of IFN-α14, we have evaluated the expression levels of some IFN-induced antiviral effectors, including OAS1, OAS2, OASL, RNase L, PKR, Mx1 and ISG15. We observed that the mRNA levels of these antiviral genes were all up-regulated to certain degrees in a dose-dependent manner when cells were treated with either IFN-α14 or IFN-α2a (Yi, et al., data not shown). However, IFN-α14 induced much stronger antiviral responses than that of conventional IFN-α2a at a low concentration (10 U/ml; Figure 5 ). For example, the mRNA levels of Mx1 and OASL induced by IFN-α14 were 125× and 63× stronger than that of IFN-α2a, respectively. This might be caused by the differential binding affinities between receptor subunits and type I IFN subtypes [22, 33] .
In conclusion, we screened 17 human type 1 IFNs, and identified four potent IFNs (IFN-α4, IFN-α6, IFN-α14 and IFN-α16) against EV71. The antiviral activity of IFN-α14 was 20× higher than that of conventional IFN-α2a, which effectively inhibited viral replication whether treated before, upon or after viral infection. IFN-α14 could be considered for anti-EV71 treatment in the future.
